Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 445877

Next Previous
Drug Profile

SAR 445877

Alternative Names: anti-PD-1/IL-15 bi-functional antibody; anti-PD-1/IL-15 fusion protein; KD-050; mut-1N-IL-15/38B2; SAR-445877; SAR-877

Latest Information Update: 18 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kadmon Corporation
  • Developer Sanofi
  • Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 replacements; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 25 Apr 2025 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research 2025 (AACR-2025)
  • 14 Apr 2023 Pharmacodynamics and adverse events data from preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 29 Nov 2022 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Netherlands and Spain (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top